Canditra SB

Adults:

100 mg and 200 mg preparations. For non-systemic fungal disease: vulvovaginal candidiasis, 200 mg twice daily for 01 day. Pityriasis versicolor, 200 mg once daily for 07 days. Tinea corporis and tinea cruris, 100 mg once daily for 15 days or 200 mg once daily for 7 days. Tinea pedis and tinea manuum, 100 mg once daily for 30 days. Oropharyngeal candidiasis, 100 mg once daily for 15 days; in AIDS or neutropenic patients the dose is increased to 200 mg once daily for 15 days because absorption is impaired in these groups. Onychomycosis (toenails with or without fingernail involvement), either 200 mg daily for 3 months, or a course (pulse) of 200 mg twice daily for 7 days, with subsequent courses repeated after a 21 day interval; fingernails need two courses and toenails three courses. For systemic fungal disease: aspergillosis, 200 mg once daily for 2 to 5 months, increased to 200 mg twice daily in invasive or disseminated disease. Candidiasis, 100 to 200 mg once daily for 3 weeks to 7 months, increased to 200 mg twice daily in invasive or disseminated disease. Non-meningeal cryptococcosis, 200 mg once daily for 10 weeks. Cryptococcal meningitis, 200 mg twice daily for 2 to 6 months. Histoplasmosis, 200 mg once daily to twice daily for 8 months. Maintenance in AIDS, 200 mg once daily until immune recovery. Prophylaxis in neutropenia, 200 mg once daily until immune recovery. The dose and duration of treatment for systemic fungal disease should be adjusted according to the clinical response. 65 mg and 130 mg preparations. For non-systemic fungal disease: vulvovaginal candidiasis, 130 mg twice daily for 1 day. Pityriasis versicolor, 65 mg twice daily for 7 days. Tinea corporis and tinea cruris, 65 mg daily for 15 days or 65 mg twice daily for 7 days. Tinea pedis and tinea manuum, 65 mg once daily for 30 days. Oropharyngeal candidiasis, 65 mg once daily for 15 days; in AIDS or neutropenic patients the dose is increased to 65 mg twice daily for 15 days because absorption is impaired in these groups. Onychomycosis (toenails with or without fingernail involvement), either 65 mg twice daily for 3 months, or a course (pulse) of 130 mg twice daily for 7 days, with subsequent courses repeated after a 21 day interval; fingernails need two courses and toenails three courses. For systemic fungal disease: aspergillosis, 65 mg twice daily for 2 to 5 months, increased to 130 mg twice daily in invasive or disseminated disease. Candidiasis, 65 to 130 mg once daily for 3 weeks to 7 months, increased to 65 mg twice daily in invasive or disseminated disease. Non-meningeal cryptococcosis, 65 mg twice daily for 10 weeks. Cryptococcal meningitis, 130 mg twice daily for 2 to 6 months. Histoplasmosis, 130 mg once daily to twice daily for 8 months. Maintenance in AIDS, 65 mg twice daily until immune recovery. Prophylaxis in neutropenia, 65 mg twice daily until immune recovery. The dose and duration of treatment for systemic antifungal disease should be adjusted according to the clinical response. 50 mg capsule. For non-systemic fungal disease (pityriasis versicolor, tinea corporis and tinea cruris, tinea pedis and tinea manuum, oropharyngeal candidiasis, and onychomycosis of the toenails with or without fingernail involvement), the dose and duration are as follows. Treatment doses: children older than 4 weeks and younger than 12 years, usual dose 1.25 to 2 mg/kg per dose (to a maximum initial dose of 100 mg) given twice daily, adjusted on the basis of therapeutic drug monitoring. For severe infections the dose may be increased to 5 mg/kg per dose (to a maximum initial dose of 100 mg) given twice daily, and the maximum daily dose may be raised further on the basis of therapeutic drug monitoring in discussion with the physicians. The dose should be rounded to the nearest 50 mg to make administration easier. Children 12 years and older, usual dose 50 mg to 100 mg once daily, which may be increased to 100 mg twice daily in severe infections. Prophylaxis doses: children 2 years and older, 2.5 mg/kg per dose given once daily (to a maximum initial dose of 200 mg daily), adjusted on the basis of therapeutic drug monitoring. For systemic fungal disease (aspergillosis, candidiasis, non-meningeal cryptococcosis, cryptococcal meningitis, and histoplasmosis), the dose and duration are as follows. Treatment doses: children older than 4 weeks and younger than 12 years, usual dose 1.25 to 2 mg/kg per dose (to a maximum initial dose of 100 mg) given twice daily, adjusted on the basis of therapeutic drug monitoring. For severe infections the dose may be increased to 5 mg/kg per dose (to a maximum initial dose of 100 mg) given twice daily, and the maximum daily dose may be raised further on the basis of therapeutic drug monitoring in discussion with the physicians. The dose should be rounded to the nearest 50 mg to make administration easier. Children 12 years and older, usual dose 50 mg to 100 mg once daily, which may be increased to 100 mg twice daily in severe infections. Prophylaxis doses: children 2 years and older, 2.5 mg/kg per dose given once daily (to a maximum initial dose of 200 mg daily), adjusted on the basis of therapeutic drug monitoring.